PERIPORTAL CARDIOMYOPATHY IN OBSTETRIC PRACTICE (CLINICAL CASE)
Main Article Content
Abstract
Peripartum cardiomyopathy in the modern sense is an exception. The European Society of Cardiology (ESC) working group defines the disease as "idiopathic cardiomyopathy, represented by heart failure due to systolic dysfunction of the left ventricle, which occurred at the end of pregnancy or within a few months after delivery. The disease is accompanied by a high mortality rate, according to various sources, 4-28 %.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Pfeffer TJ, Hilfiker-Kleiner D. Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. Curr Probl Cardiol. 2018; 43(9): 364-388. doi: 10.1016/j.cpcardiol.2017.10.005
Rudaeva EV, Mozes VG, Kashtalap VV, Zakharov IS, Yelgina SI, Rudaeva EG. Congenital heart disease and pregnancy. Fundamental and Clinical Medicine. 2019; 4(3): 102-112. Russian (Рудаева Е.В., Мозес В.Г., Кашталап В.В., Захаров И.С., Елгина С.И., Рудаева Е.Г. Врожденные пороки сердца и беременность //Фундаментальная и клиническая медицина. 2019. Т. 4, № 3. С. 102-112)
Isogai T, Chizuko A Kamiya CA. Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality. Review Int Heart J. 2019; 60(3): 503-511. doi: 10.1536/ihj.18-729
Behrens I, Basit S, Lykke JA et al. Hypertensive Disorders of Pregnancy and Peripartum Cardiomyopathy: A Nationwide Cohort Study. PLoS One. 2019; 14(2): e0211857. doi: 10.1371/journal.pone.0211857
Azibani F, Sliwa K. Peripartum Cardiomyopathy: an Update. Curr Heart Fail Rep. 2018; 15(5): 297-306. doi: 10.1007/s11897-018-0404-x
Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy. Obstet Gynecol. 2019; 133(1): 167-179. doi: 10.1097/AOG.0000000000003011
Masoomi R, Shah Z, Arany Z, Gupta K. Peripartum Cardiomyopathy: An Epidemiologic Study of Early and Late Presentations. Pregnancy Hypertens. 2018; 13: 273-278. doi: 10.1016/j.preghy.2018.06.018
Karaye KM, Ishaq NA, Sa'idu H. Incidence, Clinical Characteristics, and Risk Factors of Peripartum Cardiomyopathy in Nigeria: Results From the PEACE Registry. ESC Heart Failure. 2020; 7(1): 235-243. doi: 10.1002/ehf2.12562
Lee YZJ, Judge DP. The Role of Genetics in Peripartum Cardiomyopathy. Review J Cardiovasc Transl Res. 2017; 10(5-6): 437-445. doi: 10.1007/s12265-017-9764-y
McNamara DM, Elkayam U, Alharethi R et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy‐Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66: 905-914
Kamiya CA, Yoshimatsu J, Ikeda T. Peripartum Cardiomyopathy From a Genetic Perspective. Circ J. 2016; 80(8): 1684-1688. doi: 10.1253/circj.CJ-16-0342
Lewey J, Levine L, Elovitz M et al. Importance of Early Diagnosis in Peripartum Cardiomyopathy. Hypertension. 2020; 75(1): 91-97. doi: 10.1161/HYPERTENSIONAHA.119.13291
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart J-M et al. Recommendations of the European Society of Cardiology for the Treatment of Cardiovascular Diseases in Pregnant Women. Rational Pharmacotherapy in Cardiology. 2012; 8(3): 3-60. Russian (Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart J-M et al. Рекомендации Европейского общества кардиологов по лечению сердечно-сосудистых заболеваний у беременных //Рациональная Фармакотерапия в Кардиологии. 2012. Т. 8, № 3. С. 3-60.) https://doi.org/10.20996/1819-6446-2012-8-3-3-60
Hakata S, Umegaki T, Soeda T et al. Bromocriptine use for sudden peripartum cardiomyopathy in a patient with preeclampsia: a case report. JA Clin Rep. 2019; 5(1): 38. doi: 10.1186/s40981-019-0256-8
Onusko E, McDermott MR, Robbins N et al. Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy. PLoS One. 2020; 15(3): e0230386. doi: 10.1371/journal.pone.0230386